Dergiler / Turkish Journal of Gastroenterology / 2018 / Cilt: 29 - Sayı: 4

Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study

Sayfa
464–472
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Conclusion: Fibrotest, FIB-4, APRI, AP index and Forns index exhibit good diagnostic performance for determining liver fibrosis in CHC patients, and the use of at least two tests together will increase their diagnostic value still further.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: The hepatitis C virus (HCV) infection is important cause of chronic hepatitis.
📊
Temel Bulgular & Veri:We aimed to evaluate the diagnostic efficiency of non-invasive serum biomarkers, separately and in combinations, on liver fibrosis in treatment-naive chronic hepatitis C (CHC) patients.
💡
Sonuç & Katkı:Conclusion: Fibrotest, FIB-4, APRI, AP index and Forns index exhibit good diagnostic performance for determining liver fibrosis in CHC patients, and the use of at least two tests together will increase their diagnostic value still further.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: The hepatitis C virus (HCV) infection is important cause of chronic hepatitis. Liver biopsy is considered the gold standard for assessment of fibrosis but this procedure is an invasive procedure. We aimed to evaluate the diagnostic efficiency of non-invasive serum biomarkers, separately and in combinations, on liver fibrosis in treatment-naive chronic hepatitis C (CHC) patients. Materials and Methods: Two hundred and sixteen treatment-naive CHC patients were enrolled from 32 locations across Turkey in this open-labelled, non-interventional prospective observational study. FibroTest®, aspartate aminotransferase-to-platelet ratio index(A-PRI), aspartate aminotransferase and alanine aminotransferase ratio (AAR), fibrosis index based on four factors (FIB-4), Age-plate-let(AP) index and Forns index were measured and compared with Metavir scores got from liver biopsies. Results: Data from 182 patients with baseline liver biopsy were suitable for analysis. One hundred and twenty patients (65.9%) had F0-F1 fibrosis and 62 patients (34.1%) had F2-F4 fibrosis. APRI 0.732 area under the curve(AUC) indicated advanced fibrosis with 69% sensitivity and 77% specificity. FIB-4 0.732 AUC and FibroTest 0.715 AUC indicated advanced fibrosis with 69% and 78.4% sensitivity, and 75% and 71.4% specificity, respectively. The combined use of tests also led to an increase in AUC and specificity. Combinations of FibroTest with APRI and/or FIB-4, and FIB-4 with APRI were optimal for the evaluation of liver fibrosis. Conclusion: Fibrotest, FIB-4, APRI, AP index and Forns index exhibit good diagnostic performance for determining liver fibrosis in CHC patients, and the use of at least two tests together will increase their diagnostic value still further.

🔖

Bu Makaleye Atıf Yap

KÖKSAL, İ., YILMAZ, G., PARLAK, M., DEMİRDAL, T., KINIKLI, S., CANDAN, M., KAYA, A., AKHAN, S., AYDOĞDU, Ö., TURGUT, H., GÜRBÜZ, Y., DAĞLI, Ö., GÖKAL, A. A., GÜNER, R., KURUÜZÜM, Z., TARAKÇI, H., BESLEN, N., ERDOĞAN, S., ÖZDENER, F. (2018). Diagnostic value of combined serum biomarkers for the evaluation of liver fibrosis in chronic hepatitis C infection: A multicenter, noninterventional, observational study. Turkish Journal of Gastroenterology, Cilt: 29 - Sayı: 4, 464–472. https://ajindex.com/articles/410106

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61:77-87.
  2. Tozun N, Ozdogan O, Cakaloglu Y, et al. Seroprevalence of hepa- titis B and C virus infections and risk factors in Turkey: a fieldwork TURHEP study. Clin Microbiol Infect 2015; 21: 1020-6.
  3. Schiavon Lde L, Narciso-Schiavon JL, de Carvalho-Filho RJ. Non-invasive diagnosis of liver fibrosis in chronic hepatitis C. World J Gastroenterol 2014; 20: 2854-66.
  4. Gebo KA, Herlong HF, Torbenson MS, et al. Role of liver biopsy in management of chronic hepatitis C: a systematic review. Hepatolo- gy 2002; 36: S161-72. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.
  5. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
  6. Gressner OA, Beer N, Jodlowski A, Gressner AM. Impact of quality control accepted inter-laboratory variations on calculated Fibro- test/Actitest scores for the non-invasive biochemical assessment of liver fibrosis. Clin Chim Acta 2009; 409: 90-5.
  7. Halfon P, Munteanu M, Poynard T. Fibrotest-Actitest as a non-in- vasive marker of liver fibrosis seven years ago: a 2008 updated me- ta-analyses of FT diagnostic and prognostic values in chronic liver diseases. Gastroenterol Clin Biol 2008; 32: 22-39.
  8. Wai CT, Greenson JK, Fontana RJ, et al. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26. Mummadi RR. Role of simple biomarkers in predicting fibrosis pro- gression in HCV infection. World J Gastroenterol 2010; 16: 5710-5.
  9. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate ami- notransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-36.
  10. Sebastiani G, Alberti A. How far is non-invasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C? Journal of Vi- ral Hepatitis 2012; 19 Suppl 1: 18-32.
  11. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepa- tology 1996; 24: 289-93.
  12. Chinnaratha MA, Jeffrey GP, MacQuillan G, et al. Prediction of mor- bidity and mortality in patients with chronic hepatitis C by non-inva- sive liver fibrosis models. Liver International 2014; 34: 720-7. Sène D, Limal N, Messous D, et al. Biological markers of liver fibrosis an